利用心脏生物标志物检测和预防化疗引起的心肌病。
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.
作者信息
Singh Dhssraj, Thakur Akanksha, Tang W H Wilson
机构信息
Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, J3-4, Cleveland, OH, 44195, USA.
出版信息
Curr Heart Fail Rep. 2015 Jun;12(3):255-62. doi: 10.1007/s11897-015-0258-4.
Abstract
The success achieved in advances in cancer therapy has been marred by development of cardiotoxicity, which causes significant morbidity and mortality. This has led to the development of surveillance protocols for cardiotoxicity utilizing multimodality imaging techniques and investigation of various drugs to treat and prevent cardiotoxicity in this subset of patients. Cardiac biomarkers hold important diagnostic and prognostic value in various cardiac diseases. In this review, we discuss the use of biomarkers in patients receiving chemotherapy, highlighting data behind the use of troponin, B-type natriuretic peptide, and myeloperoxidase. We also discuss the use of dexrazoxane, angiotensin-converting enzyme inhibitors, and beta blockers in the treatment and prevention of chemotherapy-induced cardiotoxicity. Cardiac biomarkers may serve an important role in selecting patients that are at high risk of cardiotoxicity and can potentially be used to guide the administration of drugs to treat and prevent cardiotoxicity.
摘要
癌症治疗进展所取得的成功因心脏毒性的出现而受到影响，心脏毒性会导致显著的发病率和死亡率。这促使人们利用多模态成像技术制定心脏毒性监测方案，并研究各种药物来治疗和预防这类患者的心脏毒性。心脏生物标志物在各种心脏疾病中具有重要的诊断和预后价值。在本综述中，我们讨论生物标志物在接受化疗患者中的应用，重点介绍肌钙蛋白、B型利钠肽和髓过氧化物酶应用背后的数据。我们还讨论了右丙亚胺、血管紧张素转换酶抑制剂和β受体阻滞剂在治疗和预防化疗引起的心脏毒性方面的应用。心脏生物标志物在选择心脏毒性高危患者方面可能发挥重要作用，并有可能用于指导治疗和预防心脏毒性药物的给药。
相似文献
1
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.利用心脏生物标志物检测和预防化疗引起的心肌病。
Curr Heart Fail Rep. 2015 Jun;12(3):255-62. doi: 10.1007/s11897-015-0258-4.
2
Role of biomarkers in chemotherapy-induced cardiotoxicity.生物标志物在化疗引起的心脏毒性中的作用。
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):121-9. doi: 10.1016/j.pcad.2010.04.002.
3
Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use.预测化疗所致心脏毒性的生化标志物：文献系统评价及应用建议
Am J Clin Pathol. 2008 Nov;130(5):688-95. doi: 10.1309/AJCPB66LRIIVMQDR.
4
5
Cancer Therapy-Related Cardiac Dysfunction: Strategies for Enhancing Cardiac Recovery.癌症治疗相关的心脏功能障碍：增强心脏恢复的策略。
Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):109-112. doi: 10.14797/mdcvj.1430. eCollection 2024.
6
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.生物标志物在评估化疗引起的心脏毒性中的应用。
Clin Biochem. 2015 Mar;48(4-5):223-35. doi: 10.1016/j.clinbiochem.2014.10.013. Epub 2014 Nov 7.
7
[Biochemical markers for predicting chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use].
G Ital Cardiol (Rome). 2006 Sep;7(9):604-11.
8
The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.即时检测生物标志物在蒽环类化疗期间检测心脏毒性的效用：一项可行性研究。
J Card Fail. 2016 Jun;22(6):433-8. doi: 10.1016/j.cardfail.2016.04.003. Epub 2016 Apr 11.
9
The Role of Biomarkers in Cardio-Oncology.生物标志物在心肿瘤学中的作用。
J Cardiovasc Transl Res. 2020 Jun;13(3):431-450. doi: 10.1007/s12265-020-10042-3. Epub 2020 Jul 8.
10
Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.化疗所致心脏毒性：生物标志物的作用
Curr Cardiol Rep. 2015 Jul;17(7):603. doi: 10.1007/s11886-015-0603-y.
引用本文的文献
1
Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法相关的心血管毒性
Front Pharmacol. 2025 May 8;16:1578157. doi: 10.3389/fphar.2025.1578157. eCollection 2025.
2
Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies.癌症患儿心脏毒性的预后因素：定义、病因及组学技术诊断
Diagnostics (Basel). 2023 May 26;13(11):1864. doi: 10.3390/diagnostics13111864.
3
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity.某些抗高血压药物及其固定剂量组合对曲妥珠单抗介导的心脏毒性的治疗潜力
Front Pharmacol. 2021 Mar 4;11:610331. doi: 10.3389/fphar.2020.610331. eCollection 2020.
4
Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer.使用一组新型生物标志物在西弗吉尼亚州乳腺癌人群中检测蒽环类药物诱导的心脏毒性的早期发作。
Sci Rep. 2021 Apr 12;11(1):7954. doi: 10.1038/s41598-021-87209-8.
5
Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology.大流行视角：COVID-19与心脏肿瘤学的共性
Front Cardiovasc Med. 2020 Dec 4;7:568720. doi: 10.3389/fcvm.2020.568720. eCollection 2020.
6
Cardiac Toxicity and Anthracyclines: Mechanism, Interventions, and the Trouble With Troponin.心脏毒性与蒽环类药物：作用机制、干预措施及肌钙蛋白相关问题
J Adv Pract Oncol. 2019 May-Jun;10(4):360-366. doi: 10.6004/jadpro.2019.10.4.4. Epub 2019 Mar 1.
7
African Vegetables ( Leaf and Seed Extracts) Effectively Mitigate Trastuzumab-Induced Cardiotoxicity in Wistar Rats.非洲蔬菜（叶和籽提取物）有效减轻曲妥珠单抗诱导的Wistar大鼠心脏毒性。
Oxid Med Cell Longev. 2020 Oct 15;2020:9535426. doi: 10.1155/2020/9535426. eCollection 2020.
8
Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.曲妥珠单抗治疗的 HER2 阳性患者的心脏监测：综述及对临床实践的影响。
Breast. 2020 Aug;52:33-44. doi: 10.1016/j.breast.2020.04.005. Epub 2020 Apr 16.
9
Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.关于将生物标志物与影像学发现相结合用于检测和管理心脏毒性的最新进展。
Curr Cardiol Rep. 2018 Jun 22;20(8):67. doi: 10.1007/s11886-018-1009-4.
10
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.醛糖还原酶抑制剂增加结肠癌细胞对阿霉素的敏感性并降低心脏毒性。
Sci Rep. 2017 Jun 9;7(1):3182. doi: 10.1038/s41598-017-03284-w.
本文引用的文献
1
Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.二维斑点追踪超声心动图联合高敏心肌肌钙蛋白 T 早期检测蒽环类药物化疗中心脏毒性及预测。
Eur J Heart Fail. 2014 Mar;16(3):300-8. doi: 10.1002/ejhf.8. Epub 2013 Dec 30.
2
Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.早期多种生物标志物的增加可预测接受多柔比星、紫杉烷类和曲妥珠单抗治疗的乳腺癌患者随后发生心脏毒性。
J Am Coll Cardiol. 2014 Mar 4;63(8):809-16. doi: 10.1016/j.jacc.2013.10.061. Epub 2013 Nov 27.
3
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).依那普利和卡维地洛预防恶性血液病患者化疗引起的左心室收缩功能障碍：OVERCOME 试验（依那普利和卡维地洛预防接受强化化疗治疗恶性血液病患者左心室功能障碍）。
J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62. doi: 10.1016/j.jacc.2013.02.072. Epub 2013 Apr 10.
4
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.化疗、靶向药物和放疗所致心血管毒性：ESMO 临床实践指南。
Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293.
5
Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia.卡维地洛对蒽环类药物诱导的儿童急性淋巴细胞白血病左心功能障碍的保护作用。
J Card Fail. 2012 Aug;18(8):607-13. doi: 10.1016/j.cardfail.2012.06.416.
6
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.评估超声心动图和生物标志物在接受蒽环类药物、紫杉烷类药物和曲妥珠单抗治疗的患者中心脏毒性的扩展预测。
Circ Cardiovasc Imaging. 2012 Sep 1;5(5):596-603. doi: 10.1161/CIRCIMAGING.112.973321. Epub 2012 Jun 28.
7
Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management.化疗所致心肌病：发病机制、监测与管理
J Clin Med Res. 2009 Apr;1(1):8-12. doi: 10.4021/jocmr2009.02.1225. Epub 2009 Mar 24.
8
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.多柔比星诱导性心肌病：从分子机制到治疗策略。
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21.
9
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.多柔比星治疗高危儿童急性淋巴细胞白血病患者期间心脏生物标志物的变化：与长期超声心动图结果的关系。
J Clin Oncol. 2012 Apr 1;30(10):1042-9. doi: 10.1200/JCO.2010.30.3404. Epub 2012 Feb 27.
10
Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.连续测量 NT-proBNP 可预测乳腺癌患者非高剂量蒽环类药物心脏毒性。
Br J Cancer. 2011 Nov 22;105(11):1663-8. doi: 10.1038/bjc.2011.439. Epub 2011 Nov 8.
Zotero 插件